Johnson & Johnson

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval
Categories

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
Do you like it?
Read more
October 16, 2017
Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence
Categories

Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery

[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
Do you like it?
Read more
August 25, 2017
Categories

The Future of BioManufacturing: The Promise of Perfusion

Do you like it?
Read more
July 6, 2017
Global Drug Development IPOs: 27 IPOs Raise over $2.83B in Q2-2017
Categories

Global Therapeutic IPO Market on the Rise: 27 Companies Raise Over $2.83B in Q2 2017

[vc_row][vc_column][vc_column_text]   After a well-documented lull in 2016 and a sluggish start to 2017, the global therapeutic IPO market has started to bounce back in Q2, […]
Do you like it?
Read more
January 31, 2017
What Assets are J&J Actually Getting with its $30B Acquisition of Actelion?
Categories

M&A Analysis: Is Johnson & Johnson’s $30B Acquisition of Actelion Overvalued?

[vc_row][vc_column][vc_column_text] Healthcare multinational Johnson & Johnson will pay $30B to acquire Swiss drugmaker Actelion in an all-cash deal. Under the conditions of the deal, Actelion will […]
Do you like it?
Read more
Contact Us